Clinical trial NCT03244553: Treatment of Dysphagia and Ineffective Esophageal Motility With Prucalopride: A Pilot Study
Official title: Treatment of Dysphagia and Ineffective Esophageal Motility With Prucalopride: A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Ineffective Esophageal Motility
Dysphagia
Lead sponsor: University of Calgary
Sponsor class: OTHER
First posted: 2017-08-09
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will test prucalopride (a prokinetic drug currently approved by Health Canada for treatment of constipation) as a treatment for Ineffective Esophageal Motility (IEM). Adult patients with previously diagnosed IEM will be invited to participate by the investigators. The participants will take the study medication for 5 days and on the final day of medication undergo an esophageal manometry procedure at the Calgary Gut Motility Centre to measure esophageal function. Symptoms and side effects will be tracked at baseline and on Day 5.

Detailed description: As part of the standard clinical evaluation of our department, all patients presenting to the Calgary Gut Motility Centre with dysphagia routinely undergo a thorough clinical assessment including history taking and physical examination. Depending on their presentation, further evaluation may include upper endoscopy, barium swallow, esophageal manometry, and pH testing.

Patients meeting inclusion and exclusion criteria will receive prucalopride for 5 days total, with 2mg on day 1, then 4mg on days 2 to 5. On day 5 of the intervention, patients will undergo esophageal manometry. Patients will also complete a symptoms questionnaire for assessment of dysphagia symptoms and the EQ-5D questionnaire for assessment of global quality of life at baseline and on day 5 of prucalopride treatment.

Full research ethics approval will be obtained prior to commencement of the study. Participants will be recruited from patients completing esophageal manometry at the South Health Campus. Patients who have provided consent to be contacted for research studies and who have dysphagia and findings of ineffective esophageal motility (IEM) on manometry will be contacted by the study investigators. The results of their esophageal manometry will be reviewed with them, and the study will be described to them. If the patient is interested in study participation, then study investigators will arrange for the patient to come to the South Health Campus to review the study in detail prior to obtaining informed consent. Thirty patients will be enrolled in this study.

Patients who meet all inclusion and exclusion criteria will be enrolled. Once enrolled, the participants will be asked to complete a symptom and quality of life questionnaire. They will receive the prucalopride pills, to be taken for 5 days with the following instructions: Day 1, take 1 tablet (2 mg), on days 2 through 4, take 2 tablets (4mg) and on day 5, take 2 tablets 1 hour prior to the second scheduled study appointment. On day 5, the patient will be scheduled at South Health Campus for esophageal manometry. Patients will also be asked to complete a post-treatment symptom and quality of life questionnaire at that time.

Eligibility criteria: Inclusion Criteria:

* Symptom of dysphagia
* Esophageal findings consistent with ineffective esophageal motility (IEM), defined as per the Chicago Classification as ≥50% ineffective swallows. Ineffective swallows include both failed swallows, defined by an average distal contractile integral (DCI) \<100mmHg\*cm\*sec, and weak swallows, defined by an average DCI \>100 but \<450mmHg\*cm\*sec
* Normal endoscopy
* If female of childbearing potential, a negative urine pregnancy test administered 1 day prior to taking the study medication (prucalopride)
* Able to provide informed consent

Exclusion Criteria:

* Clinical evidence (on history, physical exam, or investigations) of significant cardiovascular, respiratory, gastrointestinal, hepatic, hematological, renal, neurological, or psychiatric comorbidities that may interfere with the objectives of the study and/or pose safety concerns, including pregnancy and breastfeeding
* History of cardiovascular disorder including myocardial infarction, life-threatening arrhythmias, pacemaker or defibrillator
* Estimated GFR \<30, documented within 6 months preceding study entry
* Blood electrolytes (Na, K, CL) measured within past 6 months outside of normal reference ranges
* Uncontrolled gastroesophageal reflux disease on pH testing (DeMeester score \>14.7)
* Established esophageal motility disorder, including but not limited to achalasia, spastic disorders, Esophagogastric junction (EGJ) outflow obstruction, and absent contractility
* History of gastrointestinal surgery, including hiatal hernia repair and/or fundoplication, or any major surgery in the 3 months preceding study entry
* Use of narcotics or prokinetic treatments that cannot be stopped prior to study entry
* Use of laxatives that cannot be stopped prior to study entry
* Use of tricyclic antidepressants at a dose of \>25 mg daily (stable doses of SSRIs/ SNRIs are permitted)
* Use of macrolide antibiotics (non-macrolide antibiotics are permitted)
* Participation in clinical trial with prokinetic treatment in the 30 days preceding study entry

Primary outcomes:
measure: Change in number of successful swallows
timeFrame: Baseline and on day 5 of treatment
Secondary outcomes:
measure: Change in Dysphagia Questionnaire Score
timeFrame: Baseline and on day 5 of treatment
measure: Change in EQ-5D Score
timeFrame: Baseline and on day 5 of treatment
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: University of Calgary
state: Alberta
Study officials:
affiliation: University of Calgary
name: Michelle Buresi, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: